English

Poseida Therapeutics, Inc.

EDGAR

PSTX Quarterly report (10-Q) · filed 2024-11-07

24 filing records in this dataset, filed from 2019-01-04 to 2024-11-07. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

71.7 million USD

2024 Q3 · USD

Exact inputs and evidence

Revenue: 71748000 USD Source

Operating margin

27.52%

2024 Q3 · %

Exact inputs and evidence

Operating Income: 19742000 USD Source
Revenue: 71748000 USD Source

Operating cash flow

-9.6 million USD

2024 Q3 · USD

Exact inputs and evidence

Operating Cash Flow: 13700000 USD Source
Operating Cash Flow: 23300000 USD Source

Free cash flow

-10.2 million USD

2024 Q3 · USD

Exact inputs and evidence

Operating Cash Flow: 13700000 USD Source
Operating Cash Flow: 23300000 USD Source
Capital Expenditure: 1794000 USD Source
Capital Expenditure: 1149000 USD Source

Cash and cash equivalents: 49.3 million USD 2024-09-30 Source
Exact value

49340000 USD
Long-term debt including current maturities: 30 million USD 2021-12-31 Source
Exact value

30000000 USD
Shares outstanding: 97.4 million shares 2024-09-30 Source
Exact value

97411571 shares

Reported share-count change

1.92% · 1.84 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

95573526 shares · 2023-09-30· Source
97411571 shares · 2024-09-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

151 million USD

2023-10-01 – 2024-09-30

Exact inputs and evidence

Revenue: 64703000 USD · 2023-01-01 – 2023-12-31 Source
Revenue: 39708000 USD · 2023-01-01 – 2023-09-30 Source
Revenue: 28142000 USD · 2024-01-01 – 2024-03-31 Source
Revenue: 25973000 USD · 2024-04-01 – 2024-06-30 Source
Revenue: 71748000 USD · 2024-07-01 – 2024-09-30 Source

Net income

-60.7 million USD

2023-10-01 – 2024-09-30

Exact inputs and evidence

Net income: -123400000 USD · 2023-01-01 – 2023-12-31 Source
Net income: -98081000 USD · 2023-01-01 – 2023-09-30 Source
Net income: -24274000 USD · 2024-01-01 – 2024-03-31 Source
Net income: -31371000 USD · 2024-04-01 – 2024-06-30 Source
Net income: 20235000 USD · 2024-07-01 – 2024-09-30 Source

Operating cash flow

-15.1 million USD

2023-10-01 – 2024-09-30

Exact inputs and evidence

Operating cash flow: -92200000 USD · 2023-01-01 – 2023-12-31 Source
Operating cash flow: -63423000 USD · 2023-01-01 – 2023-09-30 Source
Operating cash flow: -15100000 USD · 2024-01-01 – 2024-03-31 Source
Operating cash flow: 23300000 USD · 2024-01-01 – 2024-06-30 Source
Operating cash flow: -15100000 USD · 2024-01-01 – 2024-03-31 Source
Operating cash flow: 13700000 USD · 2024-01-01 – 2024-09-30 Source
Operating cash flow: 23300000 USD · 2024-01-01 – 2024-06-30 Source

Capital expenditure

2.1 million USD

2023-10-01 – 2024-09-30

Exact inputs and evidence

Capital expenditure: 3066000 USD · 2023-01-01 – 2023-12-31 Source
Capital expenditure: 2757000 USD · 2023-01-01 – 2023-09-30 Source
Capital expenditure: 130000 USD · 2024-01-01 – 2024-03-31 Source
Capital expenditure: 1149000 USD · 2024-01-01 – 2024-06-30 Source
Capital expenditure: 130000 USD · 2024-01-01 – 2024-03-31 Source
Capital expenditure: 1794000 USD · 2024-01-01 – 2024-09-30 Source
Capital expenditure: 1149000 USD · 2024-01-01 – 2024-06-30 Source

Free cash flow

-17.2 million USD

2023-10-01 – 2024-09-30

Exact inputs and evidence

Operating cash flow: -92200000 USD · 2023-01-01 – 2023-12-31 Source
Operating cash flow: -63423000 USD · 2023-01-01 – 2023-09-30 Source
Operating cash flow: -15100000 USD · 2024-01-01 – 2024-03-31 Source
Operating cash flow: 23300000 USD · 2024-01-01 – 2024-06-30 Source
Operating cash flow: -15100000 USD · 2024-01-01 – 2024-03-31 Source
Operating cash flow: 13700000 USD · 2024-01-01 – 2024-09-30 Source
Operating cash flow: 23300000 USD · 2024-01-01 – 2024-06-30 Source
Capital expenditure: 3066000 USD · 2023-01-01 – 2023-12-31 Source
Capital expenditure: 2757000 USD · 2023-01-01 – 2023-09-30 Source
Capital expenditure: 130000 USD · 2024-01-01 – 2024-03-31 Source
Capital expenditure: 1149000 USD · 2024-01-01 – 2024-06-30 Source
Capital expenditure: 130000 USD · 2024-01-01 – 2024-03-31 Source
Capital expenditure: 1794000 USD · 2024-01-01 – 2024-09-30 Source
Capital expenditure: 1149000 USD · 2024-01-01 – 2024-06-30 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2024-11-07.

Financial data available through: 2023-12-31.

Coverage by financial measure

Revenue: 3 of 11 periods available· newest 2023-12-31
Operating income: 5 of 11 periods available· newest 2023-12-31
Net income: 5 of 11 periods available· newest 2023-12-31
Operating cash flow: 5 of 11 periods available· newest 2023-12-31
Capital expenditure: 5 of 11 periods available· newest 2023-12-31
Total assets: 3 of 11 periods available· newest 2023-12-31
Total liabilities: 3 of 11 periods available· newest 2023-12-31
Current assets: 3 of 11 periods available· newest 2023-12-31
Current liabilities: 3 of 11 periods available· newest 2023-12-31
Cash and cash equivalents: 3 of 11 periods available· newest 2023-12-31
Long-term debt including current maturities: 1 of 11 periods available· newest 2021-12-31
Shares outstanding: 3 of 11 periods available· newest 2023-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
-50.4%

Prior period

USD 130.49 million

2022-01-01 – 2022-12-31
Current period

USD 64.7 million

2023-01-01 – 2023-12-31

Exact inputs and evidence

64703000 − 130492000 = -65789000 USD

130492000 USD · 2022-01-01 – 2022-12-31
Inspect prior input Prior source
64703000 USD · 2023-01-01 – 2023-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Poseida Therapeutics, Inc. · 2023-12-31 Poseida Therapeutics, Inc. (edgar:1661460) Year-over-year change in Revenue: -65789000 USD Concept: fundies:Revenue Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T13:57:55Z Snapshot: d8a6e76a28467c97c28a008aff620f071edf52ba7a898d8da435a6cdf44e9738 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1661460?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 64703000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1661460/000095017024027998/pstx-20231231.htm#1636714 Filing: 000095017024027998 Input fundies:Revenue: 130492000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1661460/000095017024027998/pstx-20231231.htm#1638025 Filing: 000095017024027998
The citation records this snapshot. The page link may show a newer release later.
Net income
−USD 59.4 million

Prior period

−USD 64 million

2022-01-01 – 2022-12-31
Current period

−USD 123.4 million

2023-01-01 – 2023-12-31

Exact inputs and evidence

-123400000 − -64000000 = -59400000 USD

-64000000 USD · 2022-01-01 – 2022-12-31
Inspect prior input Prior source
-123400000 USD · 2023-01-01 – 2023-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Poseida Therapeutics, Inc. · 2023-12-31 Poseida Therapeutics, Inc. (edgar:1661460) Year-over-year change in Net income: -59400000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T13:57:55Z Snapshot: d8a6e76a28467c97c28a008aff620f071edf52ba7a898d8da435a6cdf44e9738 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1661460?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -123400000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1661460/000095017024027998/pstx-20231231.htm#1935345 Filing: 000095017024027998 Input fundies:NetIncome: -64000000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1661460/000095017024027998/pstx-20231231.htm#1936088 Filing: 000095017024027998
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 65.4 million

Prior period

−USD 26.8 million

2022-01-01 – 2022-12-31
Current period

−USD 92.2 million

2023-01-01 – 2023-12-31

Exact inputs and evidence

-92200000 − -26800000 = -65400000 USD

-26800000 USD · 2022-01-01 – 2022-12-31
Inspect prior input Prior source
-92200000 USD · 2023-01-01 – 2023-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Poseida Therapeutics, Inc. · 2023-12-31 Poseida Therapeutics, Inc. (edgar:1661460) Year-over-year change in Operating cash flow: -65400000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T13:57:55Z Snapshot: d8a6e76a28467c97c28a008aff620f071edf52ba7a898d8da435a6cdf44e9738 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1661460?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -92200000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1661460/000095017024027998/pstx-20231231.htm#1936906 Filing: 000095017024027998 Input fundies:OperatingCashFlow: -26800000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1661460/000095017024027998/pstx-20231231.htm#1937677 Filing: 000095017024027998
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-21.9%

Prior period

USD 3.92 million

2022-01-01 – 2022-12-31
Current period

USD 3.07 million

2023-01-01 – 2023-12-31

Exact inputs and evidence

3066000 − 3924000 = -858000 USD

3924000 USD · 2022-01-01 – 2022-12-31
Inspect prior input Prior source
3066000 USD · 2023-01-01 – 2023-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Poseida Therapeutics, Inc. · 2023-12-31 Poseida Therapeutics, Inc. (edgar:1661460) Year-over-year change in Capital expenditure: -858000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T13:57:55Z Snapshot: d8a6e76a28467c97c28a008aff620f071edf52ba7a898d8da435a6cdf44e9738 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1661460?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 3066000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1661460/000095017024027998/pstx-20231231.htm#1865962 Filing: 000095017024027998 Input fundies:CapitalExpenditure: 3924000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1661460/000095017024027998/pstx-20231231.htm#1867292 Filing: 000095017024027998
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2023 2023-01-01 – 2023-12-31

Revenue USD 64.7 million 100% of revenue
Operating costs Derived USD 194.21 million 300% of revenue
Operating income −USD 129.5 million −200% of revenue
Tax, interest and other Derived −USD 6.1 million −9.4% of revenue
Net income −USD 123.4 million −191% of revenue

Cash

Operating cash flow −USD 92.2 million −142% of revenue
Capital expenditure USD 3.07 million 4.7% of revenue
Free cash flow Derived −USD 95.27 million −147% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2021 Operating loss: operating costs were 553% of revenue.
2022 Operating loss: operating costs were 146% of revenue.
2023 Operating loss: operating costs were 300% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2021 2021-01-01 – 2021-12-31	31238000	172649000 Derived	-141411000	-16411000 Derived	-125000000	-105134000 Derived	Source 2021-01-01 – 2021-12-31: 31238000 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -141411000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -125000000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -102500000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 2634000 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	130492000	190438000 Derived	-59946000	4054000 Derived	-64000000	-30724000 Derived	Source 2022-01-01 – 2022-12-31: 130492000 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -59946000 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -64000000 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -26800000 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 3924000 USD Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	64703000	194207000 Derived	-129504000	-6104000 Derived	-123400000	-95266000 Derived	Source 2023-01-01 – 2023-12-31: 64703000 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -129504000 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -123400000 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -92200000 USD Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 3066000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 64.7M 2023

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20212021-12-31	Revenue	31238000	Revenue: 31238000 Open source
20222022-12-31	Revenue	130492000	Revenue: 130492000 Open source
20232023-12-31	Revenue	64703000	Revenue: 64703000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-50.4% 2023

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20212021-12-31	Year over year	No prior comparable period	Revenue: 31238000 Open source
20222022-12-31	Year over year	317.7%	Revenue: 130492000 Open source Revenue: 31238000 Open source
20232023-12-31	Year over year	-50.4%	Revenue: 64703000 Open source Revenue: 130492000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -200.2% 2023

Net margin -190.7% 2023

Free cash flow margin -147.2% 2023

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20212021-12-31	Operating margin	-452.7%	Operating Income: -141411000 Open source Revenue: 31238000 Open source
20222022-12-31	Operating margin	-45.9%	Operating Income: -59946000 Open source Revenue: 130492000 Open source
20232023-12-31	Operating margin	-200.2%	Operating Income: -129504000 Open source Revenue: 64703000 Open source
20212021-12-31	Net margin	-400.2%	Net Income: -125000000 Open source Revenue: 31238000 Open source
20222022-12-31	Net margin	-49%	Net Income: -64000000 Open source Revenue: 130492000 Open source
20232023-12-31	Net margin	-190.7%	Net Income: -123400000 Open source Revenue: 64703000 Open source
20212021-12-31	Free cash flow margin	-336.6%	Revenue: 31238000 Open source Operating Cash Flow: -102500000 Open source Capital Expenditure: 2634000 Open source
20222022-12-31	Free cash flow margin	-23.5%	Revenue: 130492000 Open source Operating Cash Flow: -26800000 Open source Capital Expenditure: 3924000 Open source
20232023-12-31	Free cash flow margin	-147.2%	Revenue: 64703000 Open source Operating Cash Flow: -92200000 Open source Capital Expenditure: 3066000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -92.2M 2023

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20212021-12-31	Operating cash flow	-102500000	Operating Cash Flow: -102500000 Open source
20222022-12-31	Operating cash flow	-26800000	Operating Cash Flow: -26800000 Open source
20232023-12-31	Operating cash flow	-92200000	Operating Cash Flow: -92200000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -95.3M 2023

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20212021-12-31	Free cash flow	-105134000	Operating Cash Flow: -102500000 Open source Capital Expenditure: 2634000 Open source
20222022-12-31	Free cash flow	-30724000	Operating Cash Flow: -26800000 Open source Capital Expenditure: 3924000 Open source
20232023-12-31	Free cash flow	-95266000	Operating Cash Flow: -92200000 Open source Capital Expenditure: 3066000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

62.1% 2023

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20212021-12-31	Liabilities / assets	42%	Total Liabilities: 113098000 Open source Total Assets: 269309000 Open source
20222022-12-31	Liabilities / assets	46.7%	Total Liabilities: 164242000 Open source Total Assets: 351837000 Open source
20232023-12-31	Liabilities / assets	62.1%	Total Liabilities: 170184000 Open source Total Assets: 273885000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

3.18× 2023

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20212021-12-31	Current assets / current liabilities	4.94×	Current Assets: 213873000 Open source Current Liabilities: 43335000 Open source
20222022-12-31	Current assets / current liabilities	5.54×	Current Assets: 298563000 Open source Current Liabilities: 53885000 Open source
20232023-12-31	Current assets / current liabilities	3.18×	Current Assets: 226475000 Open source Current Liabilities: 71318000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2019 2019-01-01 – 2019-12-31	−USD 86.53 million Exact value Exact value: -86527000 USD 2019-01-01 – 2019-12-31: -86527000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Poseida Therapeutics, Inc. · 2019-12-31 Poseida Therapeutics, Inc. (edgar:1661460) Net Income: -86527000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T13:57:55Z Snapshot: d8a6e76a28467c97c28a008aff620f071edf52ba7a898d8da435a6cdf44e9738 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1661460/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -86527000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1661460/000156459021012509/pstx-20201231.xml#123159 Filing: 000156459021012509 The citation records this snapshot. The page link may show a newer release later.	−USD 64.52 million Exact value Exact value: -64518000 USD 2019-01-01 – 2019-12-31: -64518000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Poseida Therapeutics, Inc. · 2019-12-31 Poseida Therapeutics, Inc. (edgar:1661460) Operating Cash Flow: -64518000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T13:57:55Z Snapshot: d8a6e76a28467c97c28a008aff620f071edf52ba7a898d8da435a6cdf44e9738 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1661460/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -64518000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1661460/000156459021012509/pstx-20201231.xml#148040 Filing: 000156459021012509 The citation records this snapshot. The page link may show a newer release later.	USD 5.16 million Exact value Exact value: 5156000 USD 2019-01-01 – 2019-12-31: 5156000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Poseida Therapeutics, Inc. · 2019-12-31 Poseida Therapeutics, Inc. (edgar:1661460) Capital Expenditure: 5156000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T13:57:55Z Snapshot: d8a6e76a28467c97c28a008aff620f071edf52ba7a898d8da435a6cdf44e9738 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1661460/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 5156000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1661460/000156459021012509/pstx-20201231.xml#148463 Filing: 000156459021012509 The citation records this snapshot. The page link may show a newer release later.	−USD 69.67 million Calculation and evidence -64518000 − 5156000 USD Exact free cash flow: -69674000 USD 2019-01-01 – 2019-12-31: -64518000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 5156000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Poseida Therapeutics, Inc. · 2019-12-31 Poseida Therapeutics, Inc. (edgar:1661460) Free cash flow: -69674000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T13:57:55Z Snapshot: d8a6e76a28467c97c28a008aff620f071edf52ba7a898d8da435a6cdf44e9738 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1661460?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -64518000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1661460/000156459021012509/pstx-20201231.xml#148040 Filing: 000156459021012509 Input fundies:CapitalExpenditure: 5156000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1661460/000156459021012509/pstx-20201231.xml#148463 Filing: 000156459021012509 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 129.8 million Exact value Exact value: -129800000 USD 2020-01-01 – 2020-12-31: -129800000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Poseida Therapeutics, Inc. · 2020-12-31 Poseida Therapeutics, Inc. (edgar:1661460) Net Income: -129800000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T13:57:55Z Snapshot: d8a6e76a28467c97c28a008aff620f071edf52ba7a898d8da435a6cdf44e9738 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1661460/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -129800000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1661460/000156459022009681/pstx-10k_20211231.htm#2420552 Filing: 000156459022009681 The citation records this snapshot. The page link may show a newer release later.	−USD 113.3 million Exact value Exact value: -113300000 USD 2020-01-01 – 2020-12-31: -113300000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Poseida Therapeutics, Inc. · 2020-12-31 Poseida Therapeutics, Inc. (edgar:1661460) Operating Cash Flow: -113300000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T13:57:55Z Snapshot: d8a6e76a28467c97c28a008aff620f071edf52ba7a898d8da435a6cdf44e9738 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1661460/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -113300000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1661460/000156459022009681/pstx-10k_20211231.htm#2421101 Filing: 000156459022009681 The citation records this snapshot. The page link may show a newer release later.	USD 16.91 million Exact value Exact value: 16908000 USD 2020-01-01 – 2020-12-31: 16908000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Poseida Therapeutics, Inc. · 2020-12-31 Poseida Therapeutics, Inc. (edgar:1661460) Capital Expenditure: 16908000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T13:57:55Z Snapshot: d8a6e76a28467c97c28a008aff620f071edf52ba7a898d8da435a6cdf44e9738 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1661460/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 16908000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1661460/000156459022009681/pstx-10k_20211231.htm#2323590 Filing: 000156459022009681 The citation records this snapshot. The page link may show a newer release later.	−USD 130.21 million Calculation and evidence -113300000 − 16908000 USD Exact free cash flow: -130208000 USD 2020-01-01 – 2020-12-31: -113300000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 16908000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Poseida Therapeutics, Inc. · 2020-12-31 Poseida Therapeutics, Inc. (edgar:1661460) Free cash flow: -130208000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T13:57:55Z Snapshot: d8a6e76a28467c97c28a008aff620f071edf52ba7a898d8da435a6cdf44e9738 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1661460?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -113300000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1661460/000156459022009681/pstx-10k_20211231.htm#2421101 Filing: 000156459022009681 Input fundies:CapitalExpenditure: 16908000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1661460/000156459022009681/pstx-10k_20211231.htm#2323590 Filing: 000156459022009681 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 125 million Exact value Exact value: -125000000 USD 2021-01-01 – 2021-12-31: -125000000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Poseida Therapeutics, Inc. · 2021-12-31 Poseida Therapeutics, Inc. (edgar:1661460) Net Income: -125000000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T13:57:55Z Snapshot: d8a6e76a28467c97c28a008aff620f071edf52ba7a898d8da435a6cdf44e9738 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1661460/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -125000000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1661460/000095017023007030/pstx-20221231.htm#2326324 Filing: 000095017023007030 The citation records this snapshot. The page link may show a newer release later.	−USD 102.5 million Exact value Exact value: -102500000 USD 2021-01-01 – 2021-12-31: -102500000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Poseida Therapeutics, Inc. · 2021-12-31 Poseida Therapeutics, Inc. (edgar:1661460) Operating Cash Flow: -102500000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T13:57:55Z Snapshot: d8a6e76a28467c97c28a008aff620f071edf52ba7a898d8da435a6cdf44e9738 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1661460/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -102500000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1661460/000095017023007030/pstx-20221231.htm#2328678 Filing: 000095017023007030 The citation records this snapshot. The page link may show a newer release later.	USD 2.63 million Exact value Exact value: 2634000 USD 2021-01-01 – 2021-12-31: 2634000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Poseida Therapeutics, Inc. · 2021-12-31 Poseida Therapeutics, Inc. (edgar:1661460) Capital Expenditure: 2634000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T13:57:55Z Snapshot: d8a6e76a28467c97c28a008aff620f071edf52ba7a898d8da435a6cdf44e9738 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1661460/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2634000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1661460/000095017023007030/pstx-20221231.htm#2233557 Filing: 000095017023007030 The citation records this snapshot. The page link may show a newer release later.	−USD 105.13 million Calculation and evidence -102500000 − 2634000 USD Exact free cash flow: -105134000 USD 2021-01-01 – 2021-12-31: -102500000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 2634000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Poseida Therapeutics, Inc. · 2021-12-31 Poseida Therapeutics, Inc. (edgar:1661460) Free cash flow: -105134000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T13:57:55Z Snapshot: d8a6e76a28467c97c28a008aff620f071edf52ba7a898d8da435a6cdf44e9738 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1661460?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -102500000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1661460/000095017023007030/pstx-20221231.htm#2328678 Filing: 000095017023007030 Input fundies:CapitalExpenditure: 2634000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1661460/000095017023007030/pstx-20221231.htm#2233557 Filing: 000095017023007030 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 64 million Exact value Exact value: -64000000 USD 2022-01-01 – 2022-12-31: -64000000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Poseida Therapeutics, Inc. · 2022-12-31 Poseida Therapeutics, Inc. (edgar:1661460) Net Income: -64000000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T13:57:55Z Snapshot: d8a6e76a28467c97c28a008aff620f071edf52ba7a898d8da435a6cdf44e9738 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1661460/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -64000000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1661460/000095017024027998/pstx-20231231.htm#1936088 Filing: 000095017024027998 The citation records this snapshot. The page link may show a newer release later.	−USD 26.8 million Exact value Exact value: -26800000 USD 2022-01-01 – 2022-12-31: -26800000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Poseida Therapeutics, Inc. · 2022-12-31 Poseida Therapeutics, Inc. (edgar:1661460) Operating Cash Flow: -26800000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T13:57:55Z Snapshot: d8a6e76a28467c97c28a008aff620f071edf52ba7a898d8da435a6cdf44e9738 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1661460/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -26800000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1661460/000095017024027998/pstx-20231231.htm#1937677 Filing: 000095017024027998 The citation records this snapshot. The page link may show a newer release later.	USD 3.92 million Exact value Exact value: 3924000 USD 2022-01-01 – 2022-12-31: 3924000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Poseida Therapeutics, Inc. · 2022-12-31 Poseida Therapeutics, Inc. (edgar:1661460) Capital Expenditure: 3924000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T13:57:55Z Snapshot: d8a6e76a28467c97c28a008aff620f071edf52ba7a898d8da435a6cdf44e9738 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1661460/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 3924000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1661460/000095017024027998/pstx-20231231.htm#1867292 Filing: 000095017024027998 The citation records this snapshot. The page link may show a newer release later.	−USD 30.72 million Calculation and evidence -26800000 − 3924000 USD Exact free cash flow: -30724000 USD 2022-01-01 – 2022-12-31: -26800000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 3924000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Poseida Therapeutics, Inc. · 2022-12-31 Poseida Therapeutics, Inc. (edgar:1661460) Free cash flow: -30724000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T13:57:55Z Snapshot: d8a6e76a28467c97c28a008aff620f071edf52ba7a898d8da435a6cdf44e9738 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1661460?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -26800000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1661460/000095017024027998/pstx-20231231.htm#1937677 Filing: 000095017024027998 Input fundies:CapitalExpenditure: 3924000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1661460/000095017024027998/pstx-20231231.htm#1867292 Filing: 000095017024027998 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 123.4 million Exact value Exact value: -123400000 USD 2023-01-01 – 2023-12-31: -123400000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Poseida Therapeutics, Inc. · 2023-12-31 Poseida Therapeutics, Inc. (edgar:1661460) Net Income: -123400000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T13:57:55Z Snapshot: d8a6e76a28467c97c28a008aff620f071edf52ba7a898d8da435a6cdf44e9738 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1661460/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -123400000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1661460/000095017024027998/pstx-20231231.htm#1935345 Filing: 000095017024027998 The citation records this snapshot. The page link may show a newer release later.	−USD 92.2 million Exact value Exact value: -92200000 USD 2023-01-01 – 2023-12-31: -92200000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Poseida Therapeutics, Inc. · 2023-12-31 Poseida Therapeutics, Inc. (edgar:1661460) Operating Cash Flow: -92200000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T13:57:55Z Snapshot: d8a6e76a28467c97c28a008aff620f071edf52ba7a898d8da435a6cdf44e9738 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1661460/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -92200000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1661460/000095017024027998/pstx-20231231.htm#1936906 Filing: 000095017024027998 The citation records this snapshot. The page link may show a newer release later.	USD 3.07 million Exact value Exact value: 3066000 USD 2023-01-01 – 2023-12-31: 3066000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Poseida Therapeutics, Inc. · 2023-12-31 Poseida Therapeutics, Inc. (edgar:1661460) Capital Expenditure: 3066000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T13:57:55Z Snapshot: d8a6e76a28467c97c28a008aff620f071edf52ba7a898d8da435a6cdf44e9738 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1661460/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 3066000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1661460/000095017024027998/pstx-20231231.htm#1865962 Filing: 000095017024027998 The citation records this snapshot. The page link may show a newer release later.	−USD 95.27 million Calculation and evidence -92200000 − 3066000 USD Exact free cash flow: -95266000 USD 2023-01-01 – 2023-12-31: -92200000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 3066000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Poseida Therapeutics, Inc. · 2023-12-31 Poseida Therapeutics, Inc. (edgar:1661460) Free cash flow: -95266000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T13:57:55Z Snapshot: d8a6e76a28467c97c28a008aff620f071edf52ba7a898d8da435a6cdf44e9738 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1661460?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -92200000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1661460/000095017024027998/pstx-20231231.htm#1936906 Filing: 000095017024027998 Input fundies:CapitalExpenditure: 3066000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1661460/000095017024027998/pstx-20231231.htm#1865962 Filing: 000095017024027998 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

24 filings · 1,356 latest values · 1,356 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001661460, 1661460, PSTX, edgar:1661460

Also known as POSEIDA THERAPEUTICS, INC., Poseida Therapeutics, Inc.

Poseida Therapeutics, Inc.

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2023 2023-01-01 – 2023-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation